Solventum Corporation (NYSE:SOLV – Get Free Report) has been given an average rating of “Moderate Buy” by the fourteen ratings firms that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and ten have given a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $92.80.
SOLV has been the subject of several analyst reports. Benchmark restated a “buy” rating on shares of Solventum in a report on Thursday, October 8th. UBS Group upped their target price on Solventum from $95.00 to $101.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Wedbush upped their target price on Solventum from $94.00 to $101.00 and gave the stock an “outperform” rating in a report on Thursday, August 6th. Stifel Nicolaus increased their price target on Solventum from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Finally, Mizuho set a $113.00 price target on Solventum in a research note on Thursday, August 6th.
Get Our Latest Stock Report on SOLV
Solventum Stock Performance
Shares of SOLV stock opened at $85.57 on Thursday. The company’s fifty day simple moving average is $88.66 and its 200-day simple moving average is $80.67. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 1.00. The firm has a market cap of $14.57 billion, a PE ratio of 10.46, a P/E/G ratio of 1.31 and a beta of 0.63. Solventum has a 12 month low of $62.38 and a 12 month high of $94.16.
Solventum (NYSE:SOLV – Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $2.55 EPS for the quarter, topping the consensus estimate of $1.91 by $0.64. Solventum had a net margin of 17.26% and a return on equity of 25.09%. The business had revenue of $2.21 billion during the quarter, compared to analysts’ expectations of $2.15 billion. During the same quarter in the prior year, the company posted $1.69 earnings per share. The firm’s revenue was up 2.2% on a year-over-year basis. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. Equities research analysts expect that Solventum will post 7.22 EPS for the current fiscal year.
Institutional Investors Weigh In On Solventum
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. IFP Advisors Inc grew its stake in shares of Solventum by 12.7% in the third quarter. IFP Advisors Inc now owns 1,211 shares of the company’s stock valued at $107,000 after buying an additional 136 shares in the last quarter. NewEdge Advisors LLC increased its holdings in Solventum by 2.2% during the first quarter. NewEdge Advisors LLC now owns 6,707 shares of the company’s stock worth $438,000 after buying an additional 144 shares during the last quarter. HB Wealth Management LLC increased its holdings in Solventum by 3.5% during the first quarter. HB Wealth Management LLC now owns 4,292 shares of the company’s stock worth $280,000 after buying an additional 147 shares during the last quarter. Clearstead Trust LLC raised its position in Solventum by 61.0% during the first quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock worth $26,000 after acquiring an additional 150 shares in the last quarter. Finally, Diversify Advisory Services LLC raised its position in Solventum by 3.2% during the third quarter. Diversify Advisory Services LLC now owns 5,000 shares of the company’s stock worth $439,000 after acquiring an additional 153 shares in the last quarter.
About Solventum
Solventum Corporation (NYSE: SOLV) is a global healthcare company that develops products and solutions intended to improve patient care, support healthcare professionals and enhance the efficiency of healthcare systems. Its offerings serve hospitals, clinics, dental practices, laboratories, manufacturers and other healthcare-related organizations.
The company’s portfolio includes medical and surgical products such as wound-care systems, dressings, skin-protection products, sterilization assurance products and solutions used in operating rooms.
Featured Stories
- Five stocks we like better than Solventum
- Bloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline
- Why Western Digital’s AI Storage Boom Defies the Chip Sell-Off
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.
